Protagonist Therapeutics, Inc (PTGX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Available-for-sale Securities, Current |
| Current obligations | 37.18M USD | Liabilities, Current |
| Cash and equivalents | 420.08M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 362.50M USD | Marketable Securities, Current · Available-for-sale Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $37.18M | $420.08M | $362.50M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $34.55M | $193.71M | $354.07M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $45.44M | $128.39M | $438.97M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $44.94M | $113.71M | $462.40M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $35.51M | $168.54M | $401.92M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $35.11M | $139.65M | $434.71M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $47.40M | $97.25M | $321.66M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $44.58M | $131.12M | $337.60M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $41.58M | $355.64M | $208.35M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $39.91M | $172.57M | $150.07M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $21.27M | $186.73M | $154.89M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $27.87M | $230.53M | $90.22M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $26.40M | $235.38M | $78.02M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $23.23M | $127.69M | $103.07M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $31.18M | $125.74M | $111.61M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $36.75M | $152.82M | $114.62M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $40.09M | $120.24M | $171.65M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $43.46M | $98.48M | $206.81M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $44.02M | $123.67M | $203.24M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $39.16M | $120.54M | $193.76M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $42.97M | $192.41M | $161.87M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $34.52M | $83.00M | $190.48M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $40.24M | $117.36M | $188.45M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $38.56M | $83.63M | $110.35M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $35.36M | $146.24M | $62.42M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $36.37M | $60.22M | $57.30M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $35.41M | $33.01M | $100.01M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $30.78M | $50.20M | $87.50M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $33.32M | $71.14M | $54.96M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $24.50M | $70.08M | $42.47M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $26.16M | $82.23M | $46.62M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $24.10M | $87.43M | $51.09M | (m) | (m) | (m) |
| 2018-06-30 | (m) | $29.02M | $63.86M | $61.30M | (m) | (m) | (m) |
| 2018-03-31 | (m) | $33.92M | $69.58M | $65.38M | (m) | (m) | (m) |
| 2017-12-31 | (m) | $42.55M | $106.03M | $37.97M | (m) | (m) | (m) |
| 2017-09-30 | (m) | $52.25M | $50.40M | $43.19M | (m) | (m) | (m) |
| 2017-06-30 | (m) | $9.37M | $10.37M | $54.13M | (m) | (m) | (m) |
| 2017-03-31 | (m) | $7.78M | $9.52M | $53.73M | (m) | (m) | (m) |
| 2016-12-31 | (m) | $6.43M | $21.08M | $56.52M | (m) | (m) | (m) |
| 2016-09-30 | (m) | $5.35M | $96.02M | $2.50M | (m) | (m) | (m) |
| 2016-06-30 | (m) | $4.11M | $13.77M | $6.41M | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | $28.63M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $3.13M | $4.05M | $7.87M | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | $16.71M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | $3.40M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | $9.32M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $8.46M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |